- Home
- LAB vs AUTL Comparison
LAB vs AUTL Comparison
Compare LAB & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LAB | AUTL |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.4M | 431.2M |
| IPO Year | 2008 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LAB | AUTL |
|---|---|---|
| Price | $0.97 | $1.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.35 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.68 | 28.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $101,937,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $669.62 |
| Revenue Next Year | $2.63 | $79.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $0.92 | $1.11 |
| 52 Week High | $1.72 | $2.70 |
Technical Indicators
Market Signals| Indicator | LAB | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 26.50 | 48.32 |
| Support Level | N/A | $1.27 |
| Resistance Level | $1.41 | $1.74 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 5.86 | 19.35 |
Price Performance
Historical ComparisonAbout LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.